Constellation Energy (CEG)
Verdict history · CEG
Every call Verdix has made on CEG.
While a verdict holds, its return keeps accumulating from the day the call was made — it resets only when the verdict itself changes.
Click any date below to read that write-up
The prior WAIT hinged on a decisive retest of the $236–275 support zone with a reversal signal or a breakout above $288; neither materialized as the stock merely drifted 3.4% lower without a high-volume reversal. With fresh balance-sheet skepticism around the Calpine goodwill and no new bullish catalyst, the panel shifts to BALANCED: the correction remains unresolved, and waiting for a specific entry has become waiting for any directional signal.
See methodology for how verdicts are produced. Full track record →
Why the panel isn’t ready to call CEG yet — and where they disagree.
A quality business, but not at today's price — the panel is waiting for a better price or a catalyst.
NASDAQ · Utilities / Nuclear Power · 2026-07-05 · analysis, not advice
Key levels and fundamentals figures are sourced from public market data and filings. All panel verdicts, archetype reasoning, and synthesis are AI-generated analysis.
Verdict
WaitMEDIUM confidence
Why
Six investing legends on the AI-power poster child after a ~40% fall from its high: America's largest nuclear fleet with 20-year hyperscaler contracts and a federal price floor, now cut in half on a delayed reactor restart, doubled debt, and PJM worries. Most fair values sit above the price — but nearly every lens says wait for confirmation. The debate and the key levels.Level to watch
Key support 220−8.0% from 239.25
The panel's take
Verdict: WAIT · Conviction: MEDIUM · Last price: USD 239.25 (as of 2026-07-05)
Constellation is the panel's clearest "real value emerging, but wait for the tape to confirm" call. The asset is genuinely scarce and the story is real: it owns America's largest carbon-free nuclear fleet, signed 20-year power deals with Microsoft (835 MW, the Crane/Three Mile Island restart), Meta (1.1 GW, Clinton), and now Walmart, and sits on a federal nuclear production-tax-credit floor (~$40-44/MWh) that underpins the cash flows. Q1 was a beat (adjusted EPS $2.74) and full-year guidance of $11-12 was reaffirmed. Yet the stock has fallen ~40% from its ~$412 October high to a fresh 52-week low — and the reasons are specific, not just macro: the marquee Crane restart slipped from 2027 to 2031, the $26B Calpine acquisition roughly doubled long-term debt to ~$17B and layered in merchant natural-gas exposure, PJM flagged grid-reliability risk (prompting Citi to cut its target to $297), a 50-million-share Calpine lock-up overhangs the float, and executives sold into the highs back in February. The result is a genuine split: the value, growth, and forensic lenses see fair value from roughly $270 to $330 (with the analyst consensus up near $358), while the tape is broken below the 200-day and a hawkish Fed pressures every rate-sensitive utility. Crucially, even the bulls attach the same condition — "build, don't back up the truck" until the July 30 print and the restart timeline confirm the reset has overshot. On the weight of real asset value against unresolved execution and a broken chart, the synthesis is WAIT.
Key levels
Key levels · CEG
USD · as of 2026-07-05Analyst consensus target 362 USD · range 272–441
Key support & resistance and analyst consensus — educational analysis, not advice. These are not entry or exit prices. Trading involves risk of loss.
Key resistance starts at ~$262 (a ~38% retracement of the decline and nearest overhead supply), then ~$290, up to the ~$315 shelf that capped the pre-ATH run — reclaiming ~$260-270 is the level several lenses treat as the "confirmation" trigger. Key support sits at ~$220-225 (a round number and the 50% retracement of the multi-year advance), then ~$200, with a deeper structural level near ~$178 (the ~62% retracement). The analyst consensus target spans roughly USD 272 to 441, averaging near USD 362 — well above the current price (a ~50% gap), an unusual Street-versus-tape disconnect: either deep value, or models lagging the Crane delay and PJM re-rate; note Citi has already cut to $297, and the panel's more cautious lenses want the high-$200s or better.
What legendary investors think
We ran Constellation Energy past a panel of six legendary investors' frameworks.
The panel · 6 investors
The Moat CompounderValue⚫ NeutralMedium
Nuclear plants are "about as close to an irreplaceable asset as you'll find," and 20-year hyperscaler PPAs make this "a bond with a call option on AI power." But this isn't a regulated compounder — a chunk is merchant, and the Calpine deal "nearly doubled debt to ~$17B" while ROIC of 8% says "debt is doing the work." At ~22x, "down 40% doesn't make it cheap, just less expensive." Wants $180-200.
The GARP OperatorGrowth (GARP)🟢 BullishMedium
A former stalwart-turned-momentum name, now sliding toward "cyclical/asset play." Headline PEG looks cheap (~0.8-1.0), "but Calpine juiced the growth — strip it out and organic PEG is closer to 1.8-2.0." The Crane slip past 2027 is "the story slipping," and the lock-up unlocks are real supply. Wants firm organic growth and a Crane date before backing up the truck.
The Disruptive-Innovation SeekerGrowth🟢 BullishMedium
"The largest carbon-free dispatchable fleet in the country, sitting right at the AI-electrification bottleneck" — the Microsoft PPA and Crane restart can re-rate it from utility to AI infrastructure. Honest that nuclear isn't a Wright's-Law cost curve and the restart slipping to 2031 is real execution risk. The 40% drawdown reads as "disruptive-innovation volatility, not a broken thesis." 5-year view back toward $400.
The Intrinsic-Value ModelerValuation🟢 BullishMedium
A story-to-numbers DCF (16% EPS CAGR haircut from management's 20%, 9% cost of equity for the new merchant/leverage profile) yields ~$270-290 — roughly 15-20% upside. "Price and value diverged twice in six months; the pullback overshot." But won't underwrite the full 20% guidance for four straight years, and 2.25x leverage "is the lever that turns a good story into a bad one" if power prices move first.
The Forensic SkepticContrarian🟢 BullishMedium
"This is a re-rating from a bubble multiple to a reasonable one, not a broken thesis" — reaffirmed $11-12 guidance means it was cut in half on multiple compression (37x→20x), not an earnings cut. The Microsoft PPA is contracted, not vaporware. But Calpine added "$12.5B debt and $11.1B goodwill" with gas exposure, and the CEO/CFO/CGO all sold in February near the highs — "build a position, don't go max size." Intrinsic ~$300-330.
The Macro OpportunistMacro🟢 BullishMedium
"A former leader on sale, not a falling knife — but I want the tape to confirm before I get big." The theme (hyperscalers locking up nuclear baseload) is intact and durable, but the stock is below its 50- and 200-day and the Fed "isn't handing out free money." Trading position only, stop ~$225; would scale toward a core position on a reclaim of $260-270 on volume. "I'd rather buy CEG at $260 breaking out than at $239 finding a bottom."
Each view is one investing framework applied to the stock — a perspective, not advice, and identical for every reader. Signals are the panel's own scale, not a recommendation to act.
Where they agree — and where they clash
Common ground
- The asset is genuinely scarce and contracted: the largest US nuclear fleet, a federal PTC price floor, and 20-year PPAs with Microsoft, Meta, and now Walmart — a diversifying, real demand base.
- The ~40% drawdown is largely multiple compression, not an earnings collapse: Q1 beat, and $11-12 FY2026 guidance was reaffirmed.
- The valuation has reset to reasonable: ~21-22x forward and ~13x EV/EBITDA (down from ~17.5x), a PEG near 1.2, with most fair-value estimates and the analyst consensus above the price.
- The overhangs are real and specific: the Crane restart slipped to 2031, Calpine roughly doubled the debt, a 50-million-share lock-up looms, and the tape is broken below the 200-day.
The real debate
- Overshoot or fair reset? The value/growth/forensic lenses say the pullback overshot a still-growing, contracted-cash-flow business; the macro and technical lenses say a broken tape into a hawkish Fed isn't to be fought yet.
- How much does Calpine dilute the story? Bulls note it diversifies the fleet and adds accretion; the skeptics flag doubled debt, merchant gas exposure, and $11B of goodwill that "gets quietly impaired" if power prices soften.
- Is the AI-power demand durable? The PPAs are 20-year and signed; but PJM reliability worries, softening spot power prices, and "AI-power bubble" scrutiny are exactly what re-rated the multiple.
The question it comes down to: Is Constellation a scarce, contracted nuclear franchise whose 40% drawdown has handed back real value ahead of a multi-year AI-power demand wave — or a leveraged, merchant-exposed IPP whose marquee catalyst just slipped four years, where the honest move is to wait for the tape and the July print to confirm the bottom?
The numbers
| Metric | Value |
|---|---|
| Price / Market cap | USD 239.25 / ~86B |
| P/E (TTM / fwd) | ~21x / ~21–25x (vs utility-IPP median ~17x) |
| 2026 adjusted EPS (guided) | USD 11.00–12.00 (reaffirmed; Q1 adj. EPS $2.74, +28%, beat) |
| ROE / operating margin | ~16% / ~16.6% |
| EV / EBITDA | ~13x (down from ~17.5x in Q4 2025) |
| Dividend yield | ~0.7% (+10% raise) |
| Balance sheet | LT debt ~doubled to ~$17B post-Calpine (net debt/EBITDA ~2.25x; interest coverage ~9.9x); FCF ~$1.47B (Q1) |
Figures as of Q1 2026 (reported May 11) / July 5, 2026; sourced from Constellation IR/SEC filings, Investing.com, TIKR, Utility Dive, MarketBeat, StockAnalysis, GuruFocus. Q1 revenue ($11.1B, +64%) is inflated by Calpine consolidation (closed Jan 7, 2026, $40-44/MWh, IRA §45U) provides real power-price downside protection. Next print: July 30, 2026.$26B) — adjusted EPS is the reliable run-rate. The Crane/Three Mile Island restart timeline slipped from 2027 to 2031 (PJM interconnection), the single biggest concrete setback to near-term AI-power monetization. Analyst consensus ($358-372) sits well above the price; Citi cut to $297 post-PJM. Nuclear PTC floor (
The bottom line
Constellation is the panel's most constructive WAIT — a genuinely scarce asset whose price has fallen far enough to interest the value lenses, held back by a stack of execution questions that argue for patience over conviction. The bull case is real: America's largest carbon-free nuclear fleet, a federal PTC price floor, and 20-year contracts with Microsoft, Meta, and Walmart give it something closer to a bond-with-optionality than a commodity utility, and the ~40% drawdown was multiple compression against reaffirmed earnings, not an earnings cut — which is why three independent lenses put fair value between roughly $270 and $330 and the Street consensus sits near $358. But the caution is equally concrete and, right now, decisive: the marquee Crane restart slipped four years to 2031, the Calpine deal roughly doubled debt to ~$17B and added merchant gas exposure plus impairable goodwill, PJM reliability concerns just drove a fresh target cut, a 50-million-share lock-up overhangs the float, insiders sold into the highs, and the chart is broken below its 200-day into a Fed that has stopped easing. Tellingly, even the bulls say "build, don't back up the truck." What would tip the call decisively bullish is confirmation the reset overshot — a stabilizing or improving Crane timeline, visible Calpine deleveraging, a fresh hyperscaler PPA, and a reclaim of the $260-270 zone on volume. What keeps it a wait is that, until the July 30 print and the tape confirm the bottom, buyers are catching a falling former leader whose best catalyst just moved four years out — the same scarce asset will be far more compelling once the execution questions start resolving.
contact@verdixhq.com · Published 2026-07-05 · Prices as of 2026-07-05 · Time horizon: 3–12 months · No direct position held in CEG · CEG verdict history → · Methodology →
Verdix's panel is made up of AI archetypes that apply the well-documented, publicly known investment frameworks of famous investors. They are AI agents — not the investors themselves. Verdix is not affiliated with, endorsed by, or authorized by any real individual, and the archetypes do not represent any real person's actual views, holdings, or statements. Every verdict is AI-generated.
Verdix provides educational equity research and AI-generated multi-perspective analysis. Nothing here constitutes personalized investment advice or a recommendation to buy or sell any security. Verdicts are uniform across all users and do not consider your individual financial situation, risk tolerance, or objectives. Trading and investing involve substantial risk of loss. Past performance does not predict future results. Consult a licensed financial advisor before making investment decisions.
Why the panel isn’t ready to call CEG yet — and where they disagree.
A quality business, but not at today's price — the panel is waiting for a better price or a catalyst.
NASDAQ · Utilities / Nuclear Power · 2026-07-11 · analysis, not advice
Key levels and fundamentals figures are sourced from public market data and filings. All panel verdicts, archetype reasoning, and synthesis are AI-generated analysis.
Verdict
WaitMEDIUM confidence
Why
Six investing legends on Constellation after a ~35% fall from its $412 high: America's largest nuclear fleet with hyperscaler power deals and a federal price floor — and now a Crane restart pulled forward to 2027 and cleared PJM auctions — set against Calpine's doubled debt, $11B of goodwill, and a still-broken chart. Real value emerging, but the tape says wait. The debate and the key levels.Level to watch
Key support 240−4.5% from 251.38
The panel's take
Verdict: WAIT · Conviction: MEDIUM · Last price: USD 251.38 (as of 2026-07-11)
Constellation remains the panel's clearest "real value emerging, but wait for the tape to confirm" call — and the case has quietly improved since the spring. The asset is genuinely scarce and the story is intact: it owns America's largest carbon-free nuclear fleet, signed 20-year power deals with Microsoft (835 MW, the Crane/Three Mile Island restart), Meta, and now Walmart, and sits on a federal nuclear production-tax-credit floor (~$40-44/MWh, secured through 2032) that underpins the cash flows. Several overhangs the market punished it for are now easing: the Crane restart has been pulled forward toward H2 2027 (ahead of the prior 2028 plan), all PJM units cleared the 2026-27 capacity auction, and Constellation has already paid down roughly $5B of the Calpine debt. Q1 was a beat (adjusted EPS $2.74) with full-year guidance of $11-12 reaffirmed. Yet the stock is still down ~35% from its ~$412 high and trades ~20% below its 200-day, and the caution is specific: the $26B Calpine deal roughly doubled long-term debt to ~$17.5B, added $11B of goodwill and merchant natural-gas exposure, and the value and DCF lenses put fair value only around today's price. With real asset value against a broken chart and unresolved integration risk, the synthesis is WAIT.
Key levels
Key levels · CEG
USD · as of 2026-07-11Analyst consensus target 368 USD · range 297–440
Key support & resistance and analyst consensus — educational analysis, not advice. These are not entry or exit prices. Trading involves risk of loss.
Key resistance starts at ~$278 (broken prior support, now overhead supply), then ~$310 (the June failed-retest high), up to the ~$360-415 major resistance zone from the January top — reclaiming ~$278 on volume is the level the technical lenses treat as the "confirmation" trigger. Key support sits at ~$240 (the recent swing low, just above the 52-week low), then a ~$215 historical accumulation zone from the March correction, with a deeper base near ~$190. The analyst consensus target spans roughly USD 297 to 440, averaging near USD 368 — well above the current price — an unusual Street-versus-tape disconnect, though the targets are softening (Citi cut to the high-$290s on PJM transmission concerns).
What legendary investors think
We ran Constellation Energy past a panel of six legendary investors' frameworks.
The panel · 6 investors
The Moat CompounderValue⚫ NeutralMedium
"A real moat — ~55GW post-Calpine, roughly half nuclear baseload that's genuinely hard to replicate, feeding AI-driven power demand." But a ~22x P/E on a stock that fell 35% "tells me the market is repricing growth," and ~$17.5B debt with quarterly interest up to ~$253M "is real leverage now, not the pristine balance sheet I'd prefer." A good business at a fair-to-full price with digested acquisition risk — wants more margin of safety. Fair ~$260-300.
The GARP OperatorGrowth (GARP)⚫ NeutralLow
Guided 20%+ EPS growth "sounds like a fast grower, but a big chunk isn't the core fleet humming along — it's the Calpine deal bolted on (~$2/share of accretion)." That "acquisition-driven growth" is the kind he's "always nervous about." A ~1.1-1.3 PEG on guided numbers "looks fair, but I'd want two-to-three quarters of organic, non-Calpine growth before trusting the story." Would rather watch than buy the deal premium.
The Disruptive-Innovation SeekerGrowth🟢 BullishHigh
"The scarce, dispatchable baseload asset at the center of the AI-electrification convergence — the only tech that scales carbon-free power fast enough for hyperscaler demand without new-build lead times." At ~$251, below the $412 high and the ~$368 average target, "the Walmart and Microsoft deals signal a pricing-power inflection that 2027 guidance doesn't yet embed." Inelastic nuclear supply plus exponential AI power demand is "a multi-year re-rating setup, not noise."
The Intrinsic-Value ModelerValuation⚫ NeutralMedium
A DCF (2026 EPS ~$11.50, ~8-10% growth on data-center PPAs fading to 3%, ~7.5-8% WACC for the Calpine leverage step-up) yields fair value ~$235-270 — "roughly fairly valued at $251." The 35% round-trip off the highs "prices out much of the AI-datacenter euphoria — a healthier starting point," but Calpine's acquisition debt and merchant exposure "keep risk elevated versus the pre-2026 pure-nuclear profile." Wants the low-$220s for real margin of safety.
The Forensic SkepticContrarian🔴 BearishMedium
"Calpine added $11.1B of goodwill and $12.6B of assumed debt onto a balance sheet already stretched by Crane's restart." The market prices AI-power demand "as a permanent re-rating, but merchant gas margins are cyclical and PJM capacity prices can reverse fast." Goodwill is ~12% of the $90B cap "with real impairment risk if Calpine's gas fleet underperforms or Crane slips further." Wants the 10-K footnotes on purchase accounting first.
The Macro OpportunistMacro🔴 BearishMedium
"A downtrend, not a dip." Price sits ~21% below its ~$320 200-day, down ~35% YTD, just above the 52-week low, with essentially every moving average on sell. The AI-power/nuclear theme is "real and structurally intact," but "the tape is telling me the market's re-rating the multiple lower on rate and capex-timeline doubt, and I don't fight that kind of technical damage." Would rebuild on a reclaim of ~$277 on volume or a base above $240 with momentum turning up.
Each view is one investing framework applied to the stock — a perspective, not advice, and identical for every reader. Signals are the panel's own scale, not a recommendation to act.
Where they agree — and where they clash
Common ground
- The asset is genuinely scarce and contracted: America's largest nuclear fleet, a federal PTC floor through 2032, and 20-year PPAs with Microsoft, Meta, and Walmart.
- The near-term catalysts have improved: Crane restart pulled forward to ~H2 2027, PJM units cleared the capacity auction, ~$5B of Calpine debt already paid down.
- The valuation has reset to reasonable: ~22x forward and ~13x EV/EBITDA (down from ~17.5x), with the DCF roughly at the price.
- The overhangs are real: Calpine roughly doubled debt to ~$17.5B, added $11B of goodwill and merchant gas exposure, and the tape is broken below the 200-day.
The real debate
- Overshoot or fair reset? The innovation lens sees inelastic nuclear supply re-rating on AI demand; the macro and technical lenses won't fight a broken tape into rate and capex-timeline doubt.
- How much does Calpine dilute the story? Bulls note added scale and gas flexibility; skeptics flag doubled debt, cyclical merchant margins, and $11B of impairable goodwill.
- Organic or deal-driven growth? The GARP lens wants to see non-Calpine growth before trusting the 20% guide.
The question it comes down to: Is Constellation a scarce, contracted nuclear franchise whose 35% drawdown — now with an accelerated Crane restart and cleared PJM auctions — has handed back real value ahead of a multi-year AI-power wave, or a leveraged, merchant-exposed producer whose broken chart and Calpine integration risk argue for waiting until the tape and the numbers confirm the bottom?
The numbers
| Metric | Value |
|---|---|
| Price / Market cap | USD 251.38 / ~90B |
| P/E (TTM / fwd) | ~21.8x / ~21.8x (on $11.50 mid guidance) |
| 2026 adjusted EPS (guided) | USD 11.00-12.00 (reaffirmed; Q1 adj. EPS $2.74, beat) |
| Q1 2026 revenue | USD 11.12B (+64% YoY, Calpine-driven); GAAP EPS $4.49 |
| ROE / operating margin | ~16% / ~16.6% |
| EV / EBITDA | ~13.2-13.9x (down from ~17.5x in Q4 2025) |
| Balance sheet | LT debt ~$17.5B (post-Calpine; ~$5B paid down Jan-Mar); $11.1B goodwill; FCF ~$1.47B (Q1); dividend ~0.65% |
Figures as of Q1 2026 (reported May 2026) / July 11, 2026; sourced from Constellation IR/SEC filings, StockAnalysis, Yahoo Finance, Utility Dive, MarketBeat, TIKR. Q1 revenue (+64%) is inflated by Calpine consolidation (closed Jan 7, 2026, ~$26B) — adjusted EPS is the reliable run-rate. The Crane/Three Mile Island restart is now targeted for H2 2027 (pulled forward), all PJM units cleared the 2026-27 capacity auction, and $368 avg) sits above the price but is softening (Citi cut to the high-$290s on PJM transmission concerns). Next print: August 6, 2026 (Q2 2026).$5B of Calpine debt has been repaid. The nuclear PTC floor ($40-44/MWh) is secured through 2032. Analyst consensus (
The bottom line
Constellation is the panel's most constructive WAIT — a genuinely scarce asset whose price has fallen far enough to interest the value lenses, with a catalyst path that has actually improved even as the chart stays broken. The bull case is real and, in places, strengthening: America's largest carbon-free nuclear fleet, a federal PTC floor through 2032, 20-year contracts with Microsoft, Meta, and Walmart, a Crane restart now pulled forward toward H2 2027, cleared PJM capacity auctions, and roughly $5B of Calpine debt already repaid — which is why the innovation lens sees a multi-year re-rating and the Street average still sits near $368. But the caution is equally concrete and, for now, decisive: the Calpine deal roughly doubled debt to ~$17.5B and layered on $11B of impairable goodwill and merchant gas exposure, the DCF work lands only around today's price, and the chart is broken ~20% below its 200-day with the multiple still re-rating lower. Tellingly, even the constructive lenses want a lower price or organic proof before committing. What would tip the call decisively bullish is confirmation the reset overshot — a reclaim of ~$277 on volume, visible Calpine deleveraging, and a fresh hyperscaler PPA or on-track Crane milestone. What keeps it a wait is that, until the tape and the August print confirm the bottom, buyers are catching a falling former leader whose value is real but whose integration and timeline risks aren't yet resolved — the same scarce asset will be far more compelling once the execution starts showing up in the numbers.
contact@verdixhq.com · Published 2026-07-11 · Prices as of 2026-07-11 · Time horizon: 3–12 months · No direct position held in CEG · CEG verdict history → · Methodology →
Verdix's panel is made up of AI archetypes that apply the well-documented, publicly known investment frameworks of famous investors. They are AI agents — not the investors themselves. Verdix is not affiliated with, endorsed by, or authorized by any real individual, and the archetypes do not represent any real person's actual views, holdings, or statements. Every verdict is AI-generated.
Verdix provides educational equity research and AI-generated multi-perspective analysis. Nothing here constitutes personalized investment advice or a recommendation to buy or sell any security. Verdicts are uniform across all users and do not consider your individual financial situation, risk tolerance, or objectives. Trading and investing involve substantial risk of loss. Past performance does not predict future results. Consult a licensed financial advisor before making investment decisions.
Why the panel isn’t ready to call CEG yet — and where they disagree.
A quality business, but not at today's price — the panel is waiting for a better price or a catalyst.
NASDAQ · Utilities / Nuclear Power · 2026-07-18 · analysis, not advice
Key levels and fundamentals figures are sourced from public market data and filings. All panel verdicts, archetype reasoning, and synthesis are AI-generated analysis.
Verdict
WaitMEDIUM confidence
Why
Six investing lenses on Constellation stay neutral after a wick to $238 this week: America's largest nuclear fleet, 20-year hyperscaler contracts, and a federal price floor set against $17.5B of Calpine debt and a stock trading right at fair value. Every lens is waiting on the same trigger — the August 6 print. The debate and the key levels.Level to watch
Key support 240−2.4% from 246.02
The panel's take
Verdict: WAIT · Conviction: MEDIUM · Last price: USD 246.02 (as of 2026-07-18)
What changed since 2026-07-11:
- Price: USD 251.38 → 246.02 (-2.1%) — a wick to ~$238 this week before closing back at $246.02, a shallow test of the ~$240 support shelf.
- Panel: 1 of 6 → 0 of 6 now Bullish — The Disruptive-Innovation Seeker moved off Bullish, and The Forensic Skeptic and The Macro Opportunist moved off Bearish — all six lenses now converge on Neutral as the stock trades into its own DCF fair-value band.
- Trigger: the August 6 Q2 print, which will show whether the Crane restart and Calpine deleveraging are landing in the numbers.
- Verdict: WAIT (unchanged)
The synthesis lands here because the underlying business case hasn't moved: the nation's largest carbon-free nuclear fleet, 20-year contracts with Microsoft, Meta, and Walmart, and a federal production-tax-credit floor through 2032 remain genuine and scarce. What's shifted is valuation, not quality — at ~21x forward earnings against a DCF band of roughly $235-270, the stock now sits inside its own fair-value range rather than below it, leaving no margin of safety in either direction while $17.5B of post-Calpine debt and $11.1B of goodwill stay unresolved.
Key levels
Key levels · CEG
USD · as of 2026-07-18Analyst consensus target 368 USD · range 297–440
Key support & resistance and analyst consensus — educational analysis, not advice. These are not entry or exit prices. Trading involves risk of loss.
Key resistance starts at ~$278 (broken prior support, now overhead supply), then the ~$310 June failed-retest high, up to the ~$360-415 major resistance zone — a reclaim of ~$278 on volume remains the confirmation trigger the technical lenses are watching for. Key support sits at ~$240, which this week's ~$238 wick marginally undershot before closing back above it — a test-and-hold, not a breakdown — with a deeper ~$215 historical accumulation zone below and a structural base near ~$190. The analyst consensus target spans roughly USD 297 to 440, averaging near USD 368, though that average is a pre-decline anchor rather than a fresh read on the stock.
What legendary investors think
We ran Constellation Energy past a panel of six legendary investors' frameworks.
The panel · 6 investors
The Moat CompounderValue/Quality/Moat⚫ NeutralMedium
The nuclear fleet and its 20-year contracted demand from Microsoft, Meta, and Walmart plus a PTC floor through 2032 is "the kind of durable moat I like to own for decades, not months." But $17.5B of long-term debt and $11.1B of goodwill from Calpine "isn't the conservative capital structure I look for," and ~21x forward earnings against a $235-270 DCF fair value "offers no real margin of safety at $246.02." Wants the August 6 print to confirm integration before adding.
The GARP OperatorGrowth (GARP)⚫ NeutralMedium
Likes the same story he liked at $251, but "the PEG math isn't there yet, and a great story at the wrong price is still the wrong price." At ~21x this year's $11.00-12.00 guide, "that $17.5B of Calpine debt is a real balance sheet weight I want to see worked down, not just talked about." This week's wick-and-close-back is "a shallow test-and-hold, not a breakdown," but also not the $278 reclaim that would tell him sellers are done.
The Disruptive-Innovation SeekerDisruptive Innovation⚫ NeutralMedium
Still sees the platform play on AI-driven electricity demand — the Crane restart pulled forward to H2 2027 is "exactly the kind of convergence that expands the TAM for nuclear beyond what today's $88B market cap reflects." But at ~21x forward earnings with debt near $17.5B and price sitting in a bearish Supertrend zone, "this isn't a name I can size aggressively" until the chart reclaims $278 or the August 6 print confirms the thesis.
The Intrinsic-Value ModelerValuation/DCF⚫ NeutralMedium
At $246.02 against a DCF band of roughly $235-270, "this is a stock trading inside its own noise range, not one offering a margin of safety in either direction." The ~$240 shelf held on an intraweek test, but "a single wick-and-close-above doesn't validate a level" — wants either the $278 reclaim on volume or a clean breach of $240 before treating this week's action as informative. The $368 consensus is "a stale anchor from before the price decline."
The Forensic SkepticContrarian/Forensic⚫ NeutralMedium
The Calpine deal "still bothers me" — $17.5B of debt and $11.1B of goodwill on a balance sheet trading roughly in line with, not below, a $235-270 conservative DCF: "that's not a margin of safety, that's a coin flip dressed up as an investment." Price wicked to ~$238 this week, marginally undershooting the $240 shelf, still trapped in the bearish Supertrend zone since the failed $310 retest. Won't pay 21.4x forward on unconfirmed guidance with the real test — the August 6 print — three weeks out.
The Macro OpportunistMacro/Timing⚫ NeutralMedium
The tape hasn't given him anything to act on — price sitting in the red Supertrend zone since the failed ~$310 retest, this week's candle wicking to ~$238 before closing at $246.02 on a test of S1 that neither broke down nor triggered the $278 reclaim he needs to get aggressive. With $17.5B of post-Calpine debt and $11.1B of fresh goodwill against a $235-270 DCF, "no margin of safety, no liquidity tailwind" — and the Street's $368 consensus is "now 50% above the tape" with the real catalyst still three weeks out.
Each view is one investing framework applied to the stock — a perspective, not advice, and identical for every reader. Signals are the panel's own scale, not a recommendation to act.
Where they agree — and where they clash
Common ground
- The moat is real and unchanged: America's largest carbon-free nuclear fleet, 20-year PPAs with Microsoft, Meta, and Walmart, and a PTC floor through 2032.
- The stock is trading essentially at fair value, not below it — the DCF band ($235-270) roughly brackets the current $246.02 price, so there's no margin of safety either way.
- Calpine's $17.5B of debt and $11.1B of goodwill are real, unresolved balance-sheet risk, not yet resolved by this week's tape.
- This week's price action — a wick to ~$238, a close back at $246.02 — is a test of the $240 support shelf that neither confirmed a breakdown nor triggered the $278 reclaim-on-volume trigger.
- Every lens is watching the same specific catalyst: the August 6 Q2 print, which will show whether the Crane restart and Calpine deleveraging are landing in the numbers.
The real debate
- How much upside is priced in? The innovation lens still sees a platform re-rating on AI power demand beyond the $88B market cap; the macro and forensic lenses see a $368 consensus that's a stale, pre-decline anchor rather than a live signal.
- Is this a margin-of-safety stock or a coin flip? The value and valuation lenses see a fairly priced, high-quality compounder worth confirming into; the forensic lens frames the same setup as no real safety margin at all given the debt load.
The question it comes down to: With every lens agreeing the story is intact but unconfirmed, is Constellation a quality nuclear franchise fairly priced today and set to re-rate once the August 6 print validates the Calpine and Crane execution — or a fully priced stock whose balance-sheet risk means the market should demand a real discount before the next leg up?
The numbers
| Metric | Value |
|---|---|
| Price / Market cap | USD 246.02 / ~88B |
| P/E (TTM / fwd) | ~21.4x / ~21.4x (on $11.50 mid guidance) |
| 2026 adjusted EPS (guided) | USD 11.00-12.00 (reaffirmed; next print Aug 6, 2026) |
| ROE / operating margin | ~16% / ~16.6% |
| EV / EBITDA | ~13.2-13.9x |
| Balance sheet | LT debt ~$17.5B (post-Calpine); $11.1B goodwill; FCF ~$1.47B (Q1); dividend ~0.65% |
Figures as of Q1 2026 (reported May 2026) / July 18, 2026; sourced from Constellation IR/SEC filings, StockAnalysis, Yahoo Finance, TIKR. Price and market cap reflect this week's close; fundamentals are unchanged from the Q1 2026 report pending the August 6, 2026 (Q2 2026) print. The nuclear PTC floor ($40-44/MWh) remains secured through 2032. Analyst consensus ($368 avg) sits well above the current price but predates this quarter's price decline.
The bottom line
The near-term signal to watch is technical: a confirmed close above ~$278 on volume is the level every lens agrees would tip the call bullish, while a clean breach of the ~$240 shelf would open the ~$215 historical accumulation zone as the next reference point. Absent either, the August 6 Q2 print is the nearer catalyst — specifically whether Calpine deleveraging and the Crane restart's H2 2027 timeline show up as reported progress rather than guidance. A new hyperscaler contract beyond the existing Microsoft, Meta, and Walmart deals would be the one input that could move the panel from "fairly priced" toward "undervalued" before that print lands.
contact@verdixhq.com · Published 2026-07-18 · Prices as of 2026-07-18 · Time horizon: 3–12 months · No direct position held in CEG · CEG verdict history → · Methodology →
Verdix's panel is made up of AI archetypes that apply the well-documented, publicly known investment frameworks of famous investors. They are AI agents — not the investors themselves. Verdix is not affiliated with, endorsed by, or authorized by any real individual, and the archetypes do not represent any real person's actual views, holdings, or statements. Every verdict is AI-generated.
Verdix provides educational equity research and AI-generated multi-perspective analysis. Nothing here constitutes personalized investment advice or a recommendation to buy or sell any security. Verdicts are uniform across all users and do not consider your individual financial situation, risk tolerance, or objectives. Trading and investing involve substantial risk of loss. Past performance does not predict future results. Consult a licensed financial advisor before making investment decisions.
Why the panel isn’t ready to call CEG yet — and where they disagree.
A quality business, but not at today's price — the panel is waiting for a better price or a catalyst.
NASDAQ · Utilities / Nuclear Power · 2026-07-25 · analysis, not advice
Key levels and fundamentals figures are sourced from public market data and filings. All panel verdicts, archetype reasoning, and synthesis are AI-generated analysis.
Verdict
WaitMEDIUM confidence
Why
Six lenses that converged on Neutral last week now split as Constellation rallies 11.5% to test the $278 resistance line on a stack of real catalysts — a PJM capacity-auction clear, a new Walmart nuclear PPA, and a Blue Energy investment — with two lenses turning Bullish and one turning Bearish on a now-richer multiple. None of it is the August 6 print, and the reclaim line hasn't confirmed on a weekly close yet. The debate and the key levels.Level to watch
Key resistance 278+1.3% from 274.35
The panel's take
Verdict: WAIT · Conviction: MEDIUM · Last price: USD 274.35 (as of 2026-07-25)
What changed since 2026-07-18:
- Price: USD 246.02 → 274.35 (+11.5%) — a sharp reversal off the June low that has now held its gains for a second straight week, running directly into the $278 resistance shelf the panel flagged last week as the confirmation trigger.
- Panel: 0 of 6 Bullish → 2 of 6 now Bullish — The Disruptive-Innovation Seeker and The Macro Opportunist moved off Neutral on real catalysts (PJM auction clear, Blue Energy stake, Saudi nuclear pact); The Intrinsic-Value Modeler moved to Bearish as price ran through the top of its DCF band without a confirming cash-flow number; The Moat Compounder, The GARP Operator, and The Forensic Skeptic stay Neutral, still wanting the print.
- Catalysts: a cleared PJM 2028-29 capacity auction (18,875 MW, 15,700 MW nuclear), a new 176 MW/20-year Walmart Dresden nuclear PPA, a Blue Energy (modular-reactor) investment, and a US-Saudi nuclear cooperation pact — all concrete, contracted-revenue news, not just sentiment.
- New risk/offset: the rally has pushed the forward multiple from ~21.4x to ~23.8x on unchanged guidance, rally-week volume is flat-to-declining rather than expanding, and The Forensic Skeptic flags a balance-sheet figure worth watching — Q1 filings show long-term debt plus short-term borrowings north of $22B, above the "$17.5B post-Calpine" number the panel anchored to last week.
- Verdict: WAIT (unchanged)
The synthesis lands here because the week's news is genuinely additive to the moat — contracted capacity, a new hyperscaler-adjacent PPA, and policy tailwind are real inputs, not narrative — but none of it is the earnings print that would confirm Calpine deleveraging and the Crane restart are landing in the numbers, and the stock has already re-rated 11.5% in anticipation of that confirmation. The panel that unanimously converged on Neutral a week ago is now split between two lenses willing to act on the catalyst stack ahead of the print and three (plus one turning outright cautious on valuation) still waiting for the August 6 report or a confirmed close through resistance. That split, not a resolved thesis, is what keeps this a WAIT.
Key levels
Key levels · CEG
USD · as of 2026-07-25Analyst consensus target 375 USD · range 272–441
Key support & resistance and analyst consensus — educational analysis, not advice. These are not entry or exit prices. Trading involves risk of loss.
Price is now testing the $274-282 resistance band directly — two consecutive weekly highs near $279.60 with closes back at $274.35 both times, and no confirmed weekly close above ~$282 yet. The next shelf up sits near $310-314 (the April-May 2026 lower-high zone), with the September-October 2025 peak zone up near $360-415 well beyond that. On the support side, the $236-242 shelf held through a deeper test than previously understood — an intraweek undershoot to $228.63 in late June, recovering back into the band on the weekly close both that week and the following week — with the $210-220 accumulation zone and the ~$190 structural base unchanged and untested below it. The analyst consensus (~18 analysts, roughly $272-441, averaging near $375) remains supportive but largely predates this week's catalyst news and the coming print.
What legendary investors think
We ran Constellation Energy past a panel of six legendary investors' frameworks.
The panel · 6 investors
The Moat CompounderValue/Quality/Moat⚫ NeutralMedium
The PJM auction clear and the new Walmart Dresden PPA mean "the moat itself just got stronger, not weaker," but "a wonderful business getting more wonderful doesn't help you if the price already knows it." With $17.5B of Calpine debt and $11.1B of goodwill still unresolved and the stock back near its 52-week low territory of a few weeks ago having since rallied, wants "the margin of safety the business itself has just earned" before buying — not there yet.
The GARP OperatorGrowth (GARP)⚫ NeutralMedium
The Dresden deal and the PJM clear are "exactly the kind of unglamorous, contracted-revenue news that makes a story durable," but "the PEG ratio doesn't care how good the story sounds, it cares whether the earnings are catching up to the price." At ~24x on unchanged $11.00-12.00 guidance, the stock is "chasing, not investing" ahead of the print — a confirmed August 6 beat with visible deleveraging is what moves this to Bullish.
The Disruptive-Innovation SeekerDisruptive Innovation🟢 BullishMedium
The Blue Energy investment, the Saudi nuclear pact, and a new AI-data-center power program confirm "the convergence I've been pricing in" — "the TAM here isn't today's market cap, it's every gigawatt of AI compute that still needs firm, carbon-free power it doesn't have." Still wants the clean $278 close-on-volume before sizing up, since this week's move was policy-headline-driven, but calls the August 6 print "a catalyst to add to conviction, not resolve doubt about it."
The Intrinsic-Value ModelerValuation/DCF🔴 BearishLow
Price has run through the top of the $235-270 DCF band on capex intent and policy tailwind, not a reported cash-flow number: "a re-rating built on announcements is a story, not yet a cash flow — I don't raise my discounted value for a deal I haven't been able to run through the model." Wants either the band to move on confirmed guidance or the price to come back to it — right now it's the price that's moved.
The Forensic SkepticContrarian/Forensic⚫ NeutralMedium
The PJM clear is real, contracted revenue and earns credit, but a closer read of Q1 filings shows long-term debt plus short-term borrowings north of $22B — "that gap needs a footnote-level explanation before I call it noise." Forward P/E has crept to ~24x on the same unconfirmed guide, and the stock ran straight into resistance without the volume-confirmed reclaim the panel wanted: "a rally built on press releases isn't the same as a rally built on the print."
The Macro OpportunistMacro/Timing🟢 BullishMedium
"I don't need the earnings report to tell me the setup changed" — the PJM auction, the Walmart PPA, and a target bump gave the tape a real catalyst, and price ran straight at the $278 line rather than fading. Not going max size with the close still shy of $278 and the print two weeks out, but "I've learned not to wait for the last data point when the tape's already moving." A confirmed close above $278-280 on volume takes this to High conviction; a rejection back toward $260 sends it back to the sidelines.
Each view is one investing framework applied to the stock — a perspective, not advice, and identical for every reader. Signals are the panel's own scale, not a recommendation to act.
Where they agree — and where they clash
Common ground
- This week's catalysts — the PJM capacity clear, the Walmart Dresden PPA, the Blue Energy stake, the Saudi nuclear pact — are genuinely additive to the moat, not sentiment-only noise.
- None of it is the reported earnings number every lens is still waiting on; the August 6 Q2 print remains the actual confirmation event for Calpine deleveraging and the Crane restart.
- The rally has made the stock more expensive without new financial confirmation — forward P/E moved from ~21.4x to ~23.8-24x on unchanged $11.00-12.00 guidance.
- Price is testing, but has not yet confirmed, the $278 reclaim-on-volume level the whole panel set as its own trigger last week.
The real debate
- Is the catalyst stack itself confirmation, or is the market front-running the print? The innovation and macro lenses see enough real, contracted news (PJM, Walmart, Blue Energy) to act ahead of August 6; the growth, valuation, and forensic lenses see a re-rating built on announcements, not cash flow, and want the actual numbers first.
- How big is the debt overhang, really? Most of the panel still anchors to the ~$17.5B post-Calpine figure from last week; the forensic lens flags a Q1 balance-sheet read showing total debt (including short-term borrowings) north of $22B — a discrepancy nobody else in the panel addressed this week.
The question it comes down to: With the stock now sitting right on the resistance line the whole panel flagged as the confirmation trigger, is this a nuclear-AI re-rating validating itself in real time through a real catalyst stack — or a rally getting ahead of both a print and a balance-sheet number that haven't confirmed anything yet?
The numbers
| Metric | Value |
|---|---|
| Price / Market cap | USD 274.35 / ~$98B |
| P/E (TTM / fwd) | ~23.8x / ~23.8x (on $11.50 mid guidance, unchanged) |
| 2026 adjusted EPS (guided) | USD 11.00-12.00 (reaffirmed; next print Aug 6, 2026, consensus adj. EPS $2.24 for Q2) |
| ROE / operating margin | ~16.1% / ~21.9% |
| Balance sheet | LT debt ~$17.5B (post-Calpine per Q1 framing; ~$22B including short-term borrowings per Q1 filings); $11.1B goodwill; FCF ~$1.29B TTM; dividend ~0.6% yield (21% payout) |
Figures as of Q1 2026 (reported May 2026) and market data through July 24-25, 2026; sourced from StockAnalysis.com, Yahoo Finance, Financecharts.com, TipRanks, and Zacks/MarketChameleon earnings calendar. Price reflects this week's close; fundamentals are unchanged from the Q1 2026 report pending the August 6, 2026 (Q2 2026) print. Analyst consensus (~$375 average across 18 analysts, range $272-441 as of mid-July) predates the week's catalyst news and the coming print.
The bottom line
The near-term signal to watch is unchanged from last week, just closer: a confirmed weekly close above ~$278-282 on expanding volume is what the panel agrees would tip this toward Bullish, while a rejection here and a slide back toward the $236-242 shelf would keep the longer-term downtrend structure — lower highs and lower lows still intact since October — in charge, reopening the $210-220 zone as the next reference. Absent either, the August 6 Q2 print is the nearer and arguably more decisive catalyst, since it's the only event that can resolve whether Calpine deleveraging and Crane's restart timeline are showing up as reported numbers rather than press releases — and, per this week's forensic read, whether the debt figure the market is pricing off is the $17.5B post-Calpine number or something closer to $22B once short-term borrowings are counted.
contact@verdixhq.com · Published 2026-07-25 · Prices as of 2026-07-25 · Time horizon: 3–12 months · No direct position held in CEG · CEG verdict history → · Methodology →
Verdix's panel is made up of AI archetypes that apply the well-documented, publicly known investment frameworks of famous investors. They are AI agents — not the investors themselves. Verdix is not affiliated with, endorsed by, or authorized by any real individual, and the archetypes do not represent any real person's actual views, holdings, or statements. Every verdict is AI-generated.
Verdix provides educational equity research and AI-generated multi-perspective analysis. Nothing here constitutes personalized investment advice or a recommendation to buy or sell any security. Verdicts are uniform across all users and do not consider your individual financial situation, risk tolerance, or objectives. Trading and investing involve substantial risk of loss. Past performance does not predict future results. Consult a licensed financial advisor before making investment decisions.
Why the panel isn’t ready to call CEG yet — and where they disagree.
A quality business, but not at today's price — the panel is waiting for a better price or a catalyst.
NASDAQ · Utilities · 2026-08-01 · analysis, not advice
Key levels and fundamentals figures are sourced from public market data and filings. All panel verdicts, archetype reasoning, and synthesis are AI-generated analysis.
Verdict
WaitMEDIUM confidence
Why
Constellation Energy's irreplaceable nuclear fleet and AI-driven power demand thesis command broad respect across five investing archetypes, but at $262.75 the price leaves no margin of safety — every voice on the panel wants either a pullback to $230–240 or a technical breakout above $275 before committing capital, keeping the verdict at WAIT as the August 6 earnings report and unresolved PJM/FERC regulatory decisions loom.Level to watch
Key resistance 268.02+2.0% from 262.75
The panel's take
Verdict: WAIT · Conviction: MEDIUM · Last price: USD 262.75
What changed since 2026-07-25:
- Price: USD 274.35 → 262.75 (-4.23%)
- Panel: 2 of 6 → 0 of 5 now Bullish — composition also changed: added The Scuttlebutt Growth Investor; removed The Disruptive-Innovation Seeker, The Macro Opportunist
- Trigger: BUY trigger: a weekly close above $274.81 (weekly EMA20) plus resolution of PJM/FERC regulatory uncertainty, or a pullback to $230–240 without breaking $228.63. SELL trigger: a break below $228.63 on volume confirming Stage 4 distribution, or a Q2 earnings guidance cut on Aug 6 that undermines the >20% base EPS growth narrative.
- Verdict: WAIT (unchanged)
Since the prior July 25 panel at $274.35, the price has drifted another 4.2% lower into the $262 range, yet the verdict stays WAIT — the incremental move hasn't produced the clean weekly close above $274.81 that the cautious camp needs, nor has it broken $228.63 to flip the call to SELL. The panel replaced The Disruptive-Innovation Seeker and The Macro Opportunist with The Scuttlebutt Growth Investor, and the new voice reinforced rather than broke the deadlock: a 12/15 growth-quality checklist affirms the business, but the technical confirmation requirement remains unmet, keeping all five votes neutral-to-cautious and the trigger exactly where it was.
WAIT, not HOLD: the business is broadly admired (irreplaceable nuclear fleet, AI demand tailwind, 12/15 growth-quality score, 83% analyst buys), but the price objection is the dominant refrain — 3 of 5 cautious voices (The Intrinsic-Value Modeler, The Moat Compounder, The GARP Operator) explicitly want a lower price or technical confirmation, and the technical-scout reinforces that with a structurally fragile chart. There is a concrete trigger (weekly close above $274.81 or pullback to $230–240) the cautious camp is waiting on, satisfying the synthesis rule that a price/timing objection with an identifiable trigger resolves to WAIT. The lone BUSINESS dissenter (The Forensic Skeptic) argues balance-sheet fragility, but his view is outlier-weighted and does not define the split.
Key levels
Key levels · CEG
USD · as of 2026-08-01Key support & resistance and analyst consensus — educational analysis, not advice. These are not entry or exit prices. Trading involves risk of loss.
What legendary investors think
We ran Constellation Energy past a panel of 5 legendary investors' frameworks.
The panel · 5 investors
The Intrinsic-Value ModelerValuation/DCF⚫ NeutralMed
Signal: Estimated intrinsic value of $245 sits 7% below the current $262.75 price, with the base case already demanding 12% revenue CAGR and 14.5% margins — the market is pricing in the bull case becoming base case, leaving no room for disappointment on regulatory resolution or Calpine integration. Conviction: Conviction is held back by unresolved PJM/FERC regulatory overhang that is actively causing customer contracting pauses, making the margin-of-safety argument contingent on an event the company does not control.
The Forensic SkepticContrarian/Forensic🔴 BearishMed
Signal: A 43% EV/EBITDA premium to the sector median (14x vs. 9.9x) combined with $21.7B net debt, a 0.42 quick ratio, and a 1.2% FCF yield means the balance sheet provides no floor under this valuation — the market is pricing hope, not hard assets. Conviction: Conviction is reinforced by multiple independent red flags: the premium multiple, the razor-thin liquidity, the dilutive $3.1B secondary offering at $285, and nuclear decommissioning liabilities that sit off-balance-sheet — no single assumption carries the bear case.
The Scuttlebutt Growth InvestorGrowth/Management⚫ NeutralMed
Signal: A 12/15 growth-quality checklist score confirms the irreplaceable nuclear fleet, premium long-term PPAs with Microsoft and Google, and transparent management — but the stock needs a weekly close above $274.81 (the weekly EMA20) to confirm the correction is over and the growth trend is intact. Conviction: Conviction is tempered by a single contested assumption: that the current technical fragility between $228 and $274 is a temporary pause in a secular growth story rather than the early stages of a structural re-rating lower.
The Moat CompounderValue/Quality/Moat⚫ NeutralMed
Signal: The nuclear fleet moat is genuine and irreplaceable — you cannot build new plants in a decade — but at 23x earnings with $22.5B in debt and management buying back stock at $285 that now trades at $262, neither the price nor the capital allocation inspires confidence. Conviction: Conviction is held back by the unresolved tension between business quality (8/10) and valuation (5/10): the moat is real but the margin of safety is absent, and government policy remains a wild card rather than a tailwind.
The GARP OperatorGrowth (GARP)⚫ NeutralMed
Signal: A PEG ratio of 1.23 on >20% guided base EPS growth through 2029 is fair but not a steal, and the 36% decline from $413 to $259 while earnings keep rising is the kind of sentiment disconnect worth watching — but the technical picture is still messy and the stock needs to prove itself above $275 first. Conviction: Conviction is held back by the unresolved technical picture: a break above $275 on volume would confirm the turn, but until then, the risk of Stage 4 distribution below $229 remains an open question that no fundamental argument can close.
Each view is one investing framework applied to the stock — a perspective, not advice, and identical for every reader. Signals are the panel's own scale, not a recommendation to act.
Where they agree — and where they clash
Common ground
- The nuclear fleet is an irreplaceable, genuine economic moat — you cannot replicate 21 GW of 24/7 carbon-free baseload power on any reasonable timeline.
- AI-driven data center power demand is a real, durable secular tailwind, not a cyclical bump — all five archetypes acknowledge the demand thesis is structurally sound.
- Management quality is above average: leadership is transparent, long-term oriented, and has delivered on execution (Calpine integration, major PPAs, affirmed guidance).
- Regulatory uncertainty — specifically PJM/FERC rules and Three Mile Island restart approval — is the primary near-term overhang that must resolve before the business can trade on its fundamentals.
- The current price around $262 is not a bargain; every archetype either explicitly wants a lower price or technical confirmation before committing new capital.
The real debate
- The Intrinsic-Value Modeler sees fair value at $245 (7% downside), while The Forensic Skeptic sees intrinsic value at $210 (25% downside) — the gap hinges entirely on whether nuclear decommissioning liabilities and balance-sheet leverage warrant a materially higher discount rate or not.
- The Scuttlebutt Growth Investor and The GARP Operator both want technical confirmation above ~$275 before acting, but they disagree on what the current range means: the former treats $228–$274 as a healthy consolidation in a secular growth story, while the latter sees it as a fragile pattern that could tip into Stage 4 distribution.
- The Moat Compounder would happily buy at $230–240 with a margin of safety, but The Forensic Skeptic would not touch this stock above $150–180 — the same moat argument leads to dramatically different valuation conclusions because they disagree on what multiple a regulated utility with nuclear tail risk deserves.
The question it comes down to: Will PJM/FERC regulatory clarity and a confirmed Three Mile Island restart timeline arrive before the stock's technical structure resolves — either breaking above $274.81 to confirm the bull case, or breaking below $228.63 to confirm the bear case — or are investors waiting on catalysts that may not materialize before the August 6 earnings report forces a reckoning?
The numbers
| Metric | Value |
|---|---|
| Price / Market cap | USD 262.75 / n/a |
| P/E (TTM / fwd) | 22.6x–24.1x / 19.7x–24.9x |
| ROE | 16.0–16.1% |
| Operating margin | n/a |
| Dividend yield | 0.65% |
| Debt / equity | 0.65–0.66 |
| Free cash flow | USD 1.3B (FY2025) |
Figures as of 2026-08-01; sourced from EarningsMoat, AL Capital Advisory, StockAnalysis.com, and Trefis (fundamentals dated Jul 2026 – Aug 2026).
The bottom line
The August 6 earnings report is the next make-or-break event: if management reaffirms >20% base EPS growth through 2029 and the stock closes the following week above $274.81, the WAIT resolves to a BUY with conviction. If guidance is cut — even modestly — and the stock loses $228.63 on volume, the thesis fractures and the panel would likely flip to a unanimous bearish posture. Between those poles, the $230–240 range remains the historical accumulation zone where The Moat Compounder and The Intrinsic-Value Modeler would get constructive, but only if the balance sheet doesn't deteriorate further. Watch the PJM capacity auction results and any federal movement on the Three Mile Island restart — either catalyst could preempt the earnings event and resolve the regulatory overhang that is currently the single largest uncertainty holding back every archetype's conviction.
contact@verdixhq.com · Published 2026-08-01 · Prices as of 2026-08-01 · Time horizon: 3–12 months · No direct position held in CEG · CEG verdict history → · Methodology →
Verdix's panel is made up of AI archetypes that apply the well-documented, publicly known investment frameworks of famous investors. They are AI agents — not the investors themselves. Verdix is not affiliated with, endorsed by, or authorized by any real individual, and the archetypes do not represent any real person's actual views, holdings, or statements. Every verdict is AI-generated.
Verdix provides educational equity research and AI-generated multi-perspective analysis. Nothing here constitutes personalized investment advice or a recommendation to buy or sell any security. Verdicts are uniform across all users and do not consider your individual financial situation, risk tolerance, or objectives. Trading and investing involve substantial risk of loss. Past performance does not predict future results. Consult a licensed financial advisor before making investment decisions.
Why the panel isn’t ready to call CEG yet — and where they disagree.
A quality business, but not at today's price — the panel is waiting for a better price or a catalyst.
NASDAQ · Utilities · 2026-08-09 · analysis, not advice
Key levels and fundamentals figures are sourced from public market data and filings. All panel verdicts, archetype reasoning, and synthesis are AI-generated analysis.
Verdict
WaitMEDIUM confidence
Why
Seven investing frameworks examine Constellation Energy, a nuclear giant riding AI power demand, and every single one agrees the business is wonderful. The split is entirely about price: the growth-oriented voices see a fair entry at 22x forward earnings, while the value-oriented voices want 20-30% lower before committing. With the stock pinned at a critical $268 technical floor and PJM regulation unresolved, the panel lands at WAIT, not because the thesis is broken, but because the next few weeks will likely hand investors a much clearer signal.Level to watch
Key support 268.02−0.7% from 269.89
Next catalyst
Trigger to confirm the breakout: A weekly close above $279.55 (the monthly EMA20) would align the technical picture with the overwhelmingly bullish fundamental consensus and likely bring The Macro Opportunist and The Intrinsic-Value Modeler onto the buy side.The panel's take
Verdict: WAIT · Conviction: MED · Last price: 269.89
What changed since 2026-08-01:
- Price: 262.75 → 269.89 (+2.72%)
- Panel: 0 of 5 → 2 of 7 now Bullish — composition also changed: added The Macro Opportunist, The Quality Rationalist; removed none
- Trigger: BUY on a weekly close above $279.55 (monthly EMA20), which would align the technical picture with the overwhelmingly bullish fundamental consensus. Alternatively, a pullback into the $232–240 range (The Forensic Skeptic's and The Moat Compounder's margin-of-safety zone) would also flip to BUY. SELL/bearish if the stock closes a week below $268.02 (78.6% Fibonacci), confirming the monthly downtrend and opening a path to $232.67.
- Verdict: WAIT (unchanged)
Since the prior WAIT verdict at $262.75, the stock has crept 2.7% higher and added two new cautious voices (The Macro Opportunist and The Quality Rationalist), but the underlying tension is unchanged: the business keeps executing (raised guidance, Q2 beat), yet the price hasn't broken above any of the key technical levels ($279.55 monthly EMA20) or pulled back into the margin-of-safety zones ($232-240) that would resolve the split. The bullish fundamental consensus is actually stronger now, though conviction remains MEDIUM because every cautious voice still objects on price and timing, not business quality.
This is a textbook BUY vs WAIT split: the bullish voices (The GARP Operator, The Scuttlebutt Growth Investor, The Quality Rationalist) all agree the business is wonderful, while every cautious voice (the technical scout, The Intrinsic-Value Modeler, The Forensic Skeptic, The Macro Opportunist, The Moat Compounder) objects purely on price and timing. Not one questions the nuclear moat or the AI-demand thesis. The Forensic Skeptic explicitly wants $232, The Moat Compounder wants sub-$200, The Macro Opportunist wants the $279.55 close, and the technicals sit at a knife's-edge $268 pivot. With the business universally admired but the entry price contested, WAIT is the only structurally correct verdict: HOLD would misclassify a price/timing-dominant split as a business dispute.
Key levels
Key levels · CEG
USD · as of 2026-08-09Key support & resistance — educational analysis, not advice. These are not entry or exit prices. Trading involves risk of loss.
What legendary investors think
We ran Constellation Energy past a panel of 7 legendary investors' frameworks.
The panel · 7 investors
The Intrinsic-Value ModelerValuation/DCF⚫ NeutralMed
Signal: The nuclear fleet is irreplaceable and PPAs with hyperscalers provide structural revenue visibility, but at ~40x trailing earnings and a base-case fair value of $290, the market is already pricing in the moat with only 7.5% upside remaining. Conviction: A single unresolved swing factor holds this back: PJM regulatory clarity, which alone determines whether the stock re-rates toward $350+ or drifts toward the $195 bear case.
The GARP OperatorGrowth (GARP)🟢 BullishMed
Signal: CEG is a textbook fast grower with a PEG of 1.4, a forward P/E of 22x on 22% EPS growth, and a CEO who raised guidance despite headwinds: the numbers say you're paying a fair price for a growth story that's still accelerating. Conviction: Several independent signals boost conviction: raised guidance, 20 Buy ratings, $4.2B operating cash flow covering net income, and a 14% YTD drawdown that looks like temporary fear, not fundamental deterioration.
The Scuttlebutt Growth InvestorGrowth/Management⚫ NeutralMed
Signal: The PJM capacity auction clearing 18,875 MW at the $325/MW-day cap is the single most important data point here: the market for CEG's baseload power is structurally undersupplied at regulatory ceilings, and CEG scores 13 out of 15 on this archetype's growth checklist as a result. Conviction: Three independent facts reinforce conviction, all pointing the same direction: management candor (explicitly naming PJM uncertainty while raising guidance), irreplaceable nuclear assets, and a 28% implied upside to the average analyst target.
The Forensic SkepticContrarian/Forensic⚫ NeutralMed
Signal: The company delivered a Q2 beat and raised guidance, yet the stock is down 14% YTD, hedge funds are net sellers, and TTM free cash flow is just $295M on a $24B debt load: a great asset at the wrong price is still a bad investment, and 20 Buy ratings with falling price targets look like anchoring, not conviction. Conviction: The one contested assumption here is whether management will actually deliver the $8.4B FCF promised for 2026-27, a 28x leap from TTM with no track-record evidence yet, and that keeps conviction in check.
The Macro OpportunistMacro/Timing⚫ NeutralMed
Signal: The fundamental story (raised guidance, Q2 beat, irreplaceable nuclear assets feeding AI data-center demand) is a home run if the regulatory fog lifts, but the stock is pinned between a bearish monthly MACD and a nascent bullish weekly crossover at the $268 Fibonacci pivot, offering no edge until one side breaks. Conviction: Conflicting signals cap this: a 10:1 reward-to-risk ratio on paper, but only a 50% probability of the trade working given that the monthly trend is still deteriorating and the NASDAQ is breaking down.
The Quality RationalistMental Models/Quality🟢 BullishMed
Signal: Constellation owns a toll booth on a road everyone needs to travel: the largest US nuclear fleet is impossible to replicate, long-term PPAs lock in decades of revenue, and the stock is down 14% YTD purely on a regulatory scare, not a fundamental problem, which is exactly the kind of mispricing I like to exploit. Conviction: This runs strong because the moat is triple-layered (asset irreplaceability, contracted revenue, regulatory price floors), management is disciplined, and the earnings stream is compounding at 20%+. Multiple independent pillars support it, none depending on a single assumption.
The Moat CompounderValue/Quality/Moat⚫ NeutralMed
Signal: The nuclear moat is genuine and the 21% EPS growth is impressive, but free cash flow is a razor-thin $295M against $24B in net debt, so 'owner earnings' are minimal and there is no margin of safety at $270. I need the stock 20-30% lower before this becomes compelling. Conviction: This depends on two things outside today's evidence: future FCF growth that hasn't materialized yet, and a regulatory decision (PJM) that management itself cannot control.
Each view is one investing framework applied to the stock — a perspective, not advice, and identical for every reader. Signals are the panel's own scale, not a recommendation to act.
Where they agree — and where they clash
Common ground
- All seven archetypes agree the nuclear moat is genuine and nearly impossible to replicate: CEG's 21 GW fleet is a structurally scarce asset.
- Every voice acknowledges that AI/data-center electricity demand creates a real, multi-decade secular tailwind for baseload carbon-free power.
- No one disputes management's execution quality: the Q2 beat, raised FY26 guidance to $11.50-$12.50, and Calpine integration are viewed as clear positives across the panel.
- The PJM regulatory uncertainty is universally identified as the dominant swing factor separating the current price from the bullish fundamental consensus.
- Every archetype recognizes that FCF is currently thin ($295M TTM) and represents the gap between the earnings story and distributable cash. The debate is only about whether the promised ramp to $8.4B is credible.
The real debate
- The GARP Operator and The Quality Rationalist see a fair price for 22% EPS growth with a PEG of ~1.4, while The Forensic Skeptic and The Moat Compounder see no margin of safety at all, with The Forensic Skeptic valuing the stock at $240 and The Moat Compounder wanting sub-$200.
- The Scuttlebutt Growth Investor treats the PJM capacity auction clearing at the regulatory ceiling as powerful confirmation of structural undersupply, while The Macro Opportunist sees it as already discounted and focuses instead on the unresolved monthly/weekly technical conflict at the $268 pivot.
- The Intrinsic-Value Modeler lands exactly in the middle, with a fair value of $290 and only 7.5% upside, arguing the moat is real but fully priced in, while The Quality Rationalist argues a wonderful business at a fair price is always worth owning regardless of a few percentage points.
- The GARP Operator says 'buy some now, add on weakness to $240,' The Macro Opportunist says 'wait for a weekly close above $279.55,' and The Forensic Skeptic says 'wait for $232 or proven FCF': three totally different entry disciplines that all point to WAIT for slightly different reasons.
The question it comes down to: Does the combination of an irreplaceable nuclear moat, accelerating AI power demand, and a 14% YTD drawdown justify paying 22x forward earnings before there is hard evidence that free cash flow will ramp from $295M to a promised $8.4B? Or does the absence of that proof, plus unresolved PJM regulation, make patience the only rational choice at $270?
The bottom line
- Trigger to confirm the breakout: A weekly close above $279.55 (the monthly EMA20) would align the technical picture with the overwhelmingly bullish fundamental consensus and likely bring The Macro Opportunist and The Intrinsic-Value Modeler onto the buy side.
- Risk to monitor: A weekly close below $268.02 (the 78.6% Fibonacci) cracks the critical support that has held the stock through the 14% YTD decline, opening a path to $232.67 and potentially triggering a bearish call.
- Next catalyst: PJM capacity auction results or formal regulatory clarity: management has explicitly called this 'material optionality,' and resolution in either direction will be the single largest swing factor for the stock within the next 6–12 months.
- Number to watch: Q3 and Q4 free cash flow prints. The bearish case rests on the gap between promised FCF ($8.4B over 2026–27) and current reality ($295M TTM); any quarter showing a material ramp toward that promise would force the skeptics to reassess.
- Further out: Three Mile Island restart approval and execution: if the NRC greenlights the restart without material cost overruns, it validates management's ability to expand capacity within the irreplaceable nuclear fleet and adds a concrete growth leg beyond the hyperscaler PPA story.
contact@verdixhq.com · Published 2026-08-09 · Prices as of 2026-08-09 · Time horizon: 3–12 months · No direct position held in CEG · CEG verdict history → · Methodology →
Verdix's panel is made up of AI archetypes that apply the well-documented, publicly known investment frameworks of famous investors. They are AI agents — not the investors themselves. Verdix is not affiliated with, endorsed by, or authorized by any real individual, and the archetypes do not represent any real person's actual views, holdings, or statements. Every verdict is AI-generated.
Verdix provides educational equity research and AI-generated multi-perspective analysis. Nothing here constitutes personalized investment advice or a recommendation to buy or sell any security. Verdicts are uniform across all users and do not consider your individual financial situation, risk tolerance, or objectives. Trading and investing involve substantial risk of loss. Past performance does not predict future results. Consult a licensed financial advisor before making investment decisions.
Why the panel isn’t ready to call CEG yet — and where they disagree.
A quality business, but not at today's price — the panel is waiting for a better price or a catalyst.
NASDAQ · Utilities · 2026-08-15 · analysis, not advice
Key levels and fundamentals figures are sourced from public market data and filings. All panel verdicts, archetype reasoning, and synthesis are AI-generated analysis.
Verdict
WaitMEDIUM confidence
Why
Six investor archetypes weigh CEG at $282.50: everyone agrees Constellation's nuclear fleet is an irreplaceable moat riding the AI power-demand wave, but the panel splits 2–4 on whether today's price offers a margin of safety. The cautious camp wants either a breakout above $288.80 or a dip into the $236–$275 zone before acting. The verdict is WAIT — not on the business, just on the entry.Level to watch
Key resistance 288.8+2.2% from 282.5
Next catalyst
Breakout to confirm the turn: A weekly close above $288.80 (the 50-week EMA) on rising volume would validate the weekly MACD bullish crossover and re-establish a Stage 2 uptrend, flipping the call to BUY.The panel's take
Verdict: WAIT · Conviction: MED · Last price: 282.5
What changed since 2026-08-09:
- Price: 269.89 → 282.5 (+4.67%)
- Panel: 2 of 7 → 2 of 6 now Bullish — composition also changed: added The Activist Catalyst, The Asymmetric Bargainer; removed The Macro Opportunist, The Moat Compounder, The Quality Rationalist
- Trigger: BUY on either (a) a weekly close above $288.80 (50-week EMA) with rising volume, confirming the weekly MACD bullish crossover and re-establishing Stage 2 uptrend; OR (b) a retest of $236–$275 support zone (monthly horizontal at $236.30, monthly Fib 38.2% at $275.16, weekly Fib 78.6% at $268.02), providing adequate margin of safety. SELL if nuclear outage frequency rises materially, a major PPA is cancelled, or Crane restart faces regulatory reversal — any of which would crack the moat thesis and re-rate the stock to utility multiples ($165–200).
- Verdict: WAIT (unchanged)
Since the prior WAIT at $269.89, the price has crept 4.7% higher to $282.50 with no new business-level catalyst to justify paying up: Q2 was already digested then, and the added voices (The Activist Catalyst, The Asymmetric Bargainer) reinforced the same price/timing objection the panel already held. The verdict holds at WAIT because the business is still excellent and the entry is still not — the stock drifted toward resistance without resolving the panel's single shared condition for action.
The panel does not dispute CEG's business quality — even the bears concede the nuclear moat is real. But this is a BUY vs WAIT split, not BUY vs SELL: the bulls (The Scuttlebutt Growth Investor, The GARP Operator) and the cautious camp (The Asymmetric Bargainer, The Forensic Skeptic, The Activist Catalyst, The Intrinsic-Value Modeler) all agree the business is excellent; the disagreement is purely about whether $264–$282 is the right entry price. The Intrinsic-Value Modeler is the sole BUSINESS objector (fair value $156–178), and his outlier DCF is overwhelmed by the rest of the cautious camp citing PRICE/TIMING — they want CEG, just at a lower price or after a confirmed technical trigger. Per Step B, a BUY vs WAIT split synthesizes to WAIT. Per Step C, price is the single blocker (business not in question), and there is an identifiable trigger ($288.80 reclaim or $236–$275 support retest), confirming WAIT. The verdict is WAIT, not BALANCED, because no genuine business-level disagreement divides the panel — only patience on entry.
Key levels
Key levels · CEG
USD · as of 2026-08-15Key support & resistance — educational analysis, not advice. These are not entry or exit prices. Trading involves risk of loss.
What legendary investors think
We ran Constellation Energy past a panel of 6 legendary investors' frameworks.
The panel · 6 investors
The Intrinsic-Value ModelerValuation/DCF🔴 BearishMed
Signal: At $167 fair value on a 7.5% WACC, a stock trading at 27x trailing earnings and 339x free cash flow is pricing in a bull case that requires 12% revenue CAGR and 18% margins just to justify the current quote, leaving no cushion if nuclear capex stays heavy or PPA growth normalizes. Conviction: Conviction is restrained by the sheer gap between the DCF-derived range ($156–178) and market price: even the bull case barely touches $272, so the entire investment case hinges on sustained above-normal growth that history suggests rarely persists for capital-intensive generators.
The GARP OperatorGrowth (GARP)🟢 BullishMed
Signal: Earnings up 66% year-over-year while the stock sits 25% below its highs, compressing the PEG to 1.5 on a forward P/E of 23.3 — a disconnect where the business is accelerating and the market has stopped paying attention. Conviction: Conviction gets a boost from multiple reinforcing signals: insider buying, a weekly MACD bullish crossover, and a guidance raise all landing at the same time the stock trades near monthly Fibonacci support.
The Forensic SkepticContrarian/Forensic⚫ NeutralLow
Signal: Twenty-two analysts with zero sell ratings and the stock still down 25% YTD: consensus euphoria paired with price weakness is the signature of a crowded trade where the easy money has already been extracted. Conviction: What caps conviction is the thin FCF — just $295 million against a $90 billion market cap — which means the company cannot self-fund its growth narrative without sustained capital-market access.
The Asymmetric BargainerContrarian/Deep Value⚫ NeutralMed
Signal: The moat is genuine — an irreplaceable 22 GW nuclear fleet selling 20-year PPAs to investment-grade hyperscalers — but at 339x P/FCF, the market is charging a perfection premium for a business that still eats nearly all its operating cash flow in maintenance capex. Conviction: Conviction is held back because the Dhandho framework demands limited downside, and here a 25–35% drawdown to $185–210 is a live scenario if the multiple merely compresses to a utility-appropriate 18x forward earnings.
The Scuttlebutt Growth InvestorGrowth/Management🟢 BullishHigh
Signal: A 15-for-15 checklist score anchored by a 94.6% nuclear capacity factor — four points above the industry average — and 920 MW of new long-dated PPAs signed in a single quarter confirms a business whose operational edge is widening, not merely sustaining. Conviction: Conviction runs high because the three The Scuttlebutt Growth Investor sell tests all fail: the monopolistic nuclear thesis is intact, competitive position is strengthening quarter-over-quarter, and management is transparently aligned through insider purchases and buybacks.
The Activist CatalystActivist/Capital Allocation⚫ NeutralMed
Signal: Management is executing the playbook — Q2 beat, guidance raised, Crane regulatory approvals secured, Calpine divestitures on track — yet the stock has declined 25% in 2026 anyway, flagging a market that is pricing macro anxiety, not company-specific deterioration. Conviction: Conviction is tempered by the lack of a clear catalyst to close that gap near-term: the entry sits in technical no-man's-land between resistance at $288.80 and support at $236, and absent a breakout or breakdown, capital is better held in reserve.
Each view is one investing framework applied to the stock — a perspective, not advice, and identical for every reader. Signals are the panel's own scale, not a recommendation to act.
Where they agree — and where they clash
Common ground
- All six archetypes agree CEG's nuclear fleet is a genuine, durable moat — assets that cannot be replicated due to regulatory, permitting, and cost barriers.
- Every voice on the panel acknowledges the structural demand tailwind from AI and hyperscaler data-center load growth is real and multi-year.
- None of the six argues the business is deteriorating; Q2 results beat estimates, guidance was raised, and the operational metrics (capacity factor, PPA signings) are improving.
- Every cautious voice shares the same blocker: price. They want CEG — just not at $282.
- The panel converges on two concrete conditions that would flip the call: a weekly close above $288.80 (50-week EMA) on volume, or a pullback into the $236–$275 support zone.
The real debate
- The Intrinsic-Value Modeler sees a $156–178 fair value and argues the market is mispricing a commoditized, capex-heavy generator as a growth compounder, while The Scuttlebutt Growth Investor scores the company 15/15 on qualitative durability and sees the pullback as an accumulation opportunity for a multi-decade holding.
- The Forensic Skeptic and The Asymmetric Bargainer both flag the 339x P/FCF and the zero-sell-rating consensus as evidence that bullishness is fully baked in, whereas The GARP Operator treats the same facts — a beaten-down stock with rising earnings — as a classic Lynchian disconnect to exploit.
- The Activist Catalyst and The Asymmetric Bargainer diverge on execution confidence: The Activist Catalyst rates management 8/10 and sees the Calpine integration progressing smoothly, while The Asymmetric Bargainer points to the complexity that Calpine's gas, retail, and merchant layers add to what was once a pure nuclear story.
The question it comes down to: Is the market's ~25% YTD haircut on CEG a genuine discount on a compounding nuclear monopoly — or is it a rational repricing of a crowded AI-adjacent trade that had simply overshot fair value?
The bottom line
- Breakout to confirm the turn: A weekly close above $288.80 (the 50-week EMA) on rising volume would validate the weekly MACD bullish crossover and re-establish a Stage 2 uptrend, flipping the call to BUY.
- Pullback zone for accumulation: A retest of the $236–$275 support band — monthly horizontal at $236.30, monthly Fib 38.2% at $275.16, weekly Fib 78.6% at $268.02 — would provide the margin of safety the cautious camp requires.
- Risk to monitor closely: Any material rise in nuclear outage frequency, a cancellation of a major PPA, or a regulatory reversal on the Crane restart would crack the moat thesis and could re-rate the stock toward utility multiples of $165–200.
- Next catalyst: Q3 2026 earnings (expected October/November) will reveal whether Calpine integration margins are tracking and whether the nuclear outage headwind flagged in Q2 has been resolved — both are prerequisites for the multiple to sustain.
contact@verdixhq.com · Published 2026-08-15 · Prices as of 2026-08-15 · Time horizon: 3–12 months · No direct position held in CEG · CEG verdict history → · Methodology →
Verdix's panel is made up of AI archetypes that apply the well-documented, publicly known investment frameworks of famous investors. They are AI agents — not the investors themselves. Verdix is not affiliated with, endorsed by, or authorized by any real individual, and the archetypes do not represent any real person's actual views, holdings, or statements. Every verdict is AI-generated.
Verdix provides educational equity research and AI-generated multi-perspective analysis. Nothing here constitutes personalized investment advice or a recommendation to buy or sell any security. Verdicts are uniform across all users and do not consider your individual financial situation, risk tolerance, or objectives. Trading and investing involve substantial risk of loss. Past performance does not predict future results. Consult a licensed financial advisor before making investment decisions.
The panel’s split verdict on CEG — and where they disagree.
The case for and against roughly balance — no clear edge at today's price.
NASDAQ · Utilities · 2026-08-22 · analysis, not advice
Key levels and fundamentals figures are sourced from public market data and filings. All panel verdicts, archetype reasoning, and synthesis are AI-generated analysis.
Verdict
BalancedMEDIUM confidence
Why
Five investing archetypes confront Constellation Energy at $272.88, where the AI-driven electricity demand story is real and accelerating but the Calpine acquisition's $24 billion debt load and near-zero free cash flow leave no margin of safety. The panel splits 2-3 with zero bears, landing at BALANCED while waiting for a decisive technical signal to resolve the standoff.Level to watch
Key resistance 275.84+1.1% from 272.88
Next catalyst
Trigger to confirm the breakout: A weekly close above $288, which coincides with the weekly EMA50 and a high-volume node top, would confirm the correction is over and shift the panel's bias decisively bullish.The panel's take
Verdict: BALANCED · Conviction: MEDIUM · Last price: 272.88 · Changed from WAIT
Panel: 2 Bullish · 3 Neutral · 0 Bearish → BALANCED
What changed since 2026-08-15:
- Price: 282.5 → 272.88 (-3.41%)
- Panel: 2 of 6 → 2 of 5 now Bullish — composition also changed: added The Disruptive-Innovation Seeker, The Moat Compounder; removed The Activist Catalyst, The Asymmetric Bargainer, The Scuttlebutt Growth Investor
- Trigger: A weekly close above $288 (weekly EMA50, high-volume node top) would confirm the correction is over and flip to BUY. A drop below $228.63 (the weekly swing low, reinforced by the monthly 50% Fib at $232.67) would break structural support and flip to SELL.
- Verdict: WAIT → BALANCED
The prior WAIT hinged on a decisive retest of the $236–275 support zone with a reversal signal or a breakout above $288; neither materialized as the stock merely drifted 3.4% lower without a high-volume reversal. With fresh balance-sheet skepticism around the Calpine goodwill and no new bullish catalyst, the panel shifts to BALANCED: the correction remains unresolved, and waiting for a specific entry has become waiting for any directional signal.
The panel splits 2-3 with zero bears: The GARP Operator and The Moat Compounder see a quality nuclear franchise with real AI-demand tailwinds but concede valuation is fair, not cheap; The Intrinsic-Value Modeler and The Forensic Skeptic object on price — the growth story is largely in the tape at a 22x forward P/E with negligible FCF yield and $24B of net debt; The Disruptive-Innovation Seeker objects on framework (not a disruptive innovator). With no outright sell case and no compelling buy case at $272.88, BALANCED is the arithmetic reading. The prior WAIT trigger has not fired: price drifted into the upper end of the $236–275 support zone but has not staged a decisive retest with a reversal signal, and the weekly EMA50 ($288) remains untested.
Key levels
Key levels · CEG
USD · as of 2026-08-22Analyst consensus target 347.5 USD · range 290–441
Key support & resistance and analyst consensus — educational analysis, not advice. These are not entry or exit prices. Trading involves risk of loss.
Key resistance at $275–276 is the confluence of the monthly 38.2% Fibonacci retracement ($275.16) and the weekly EMA20 ($275.84) — price sat just below this band at the August 17 close and has been rejected by it since the correction began. Above that, the weekly EMA50 at $288.17 is the level that must clear to end the intermediate downtrend. Key support at $268.02 is the weekly 78.6% Fibonacci retracement; the weekly swing low at $228.63 forms a historical accumulation zone alongside the monthly 50% Fib at $232.67. The analyst consensus target of $347.50 sits 27% above the current price.
What legendary investors think
We ran Constellation Energy past a panel of 5 legendary investors' frameworks.
The panel · 5 investors
The Intrinsic-Value ModelerValuation/DCF⚫ NeutralMed
Signal: The base-case DCF lands at roughly $275 per share, with the AI-driven power demand story already reflected in forward estimates that imply 20% revenue growth tapering to 12% before settling at 3% terminal growth. Conviction: Conviction remains tempered because the $24B net debt load and near-zero FCF yield ($295M TTM) leave almost no cushion if the growth trajectory stalls even slightly.
The GARP OperatorGrowth (GARP)🟢 BullishMed
Signal: CEG has locked in 920 MW of long-term PPAs averaging 18.5 years with hyperscalers, while Q2 earnings beat estimates and management raised full-year guidance to $11.50–$12.50, confirming the AI data-center demand story is accelerating, not slowing. Conviction: What gives me confidence is the combination of a manageable PEG of 1.4, a 75% beat rate on earnings, and an insider director buying $418K on the open market: three independent signals that the growth is real and not yet exhausted.
The Disruptive-Innovation SeekerDisruptive Innovation⚫ NeutralLow
Signal: Nuclear generation sits in the late majority of a mature S-curve, and CEG's role is enabling AI disruption rather than originating one. The company lacks proprietary technology, Wright's Law cost curves, or platform dynamics that drive exponential returns. Conviction: The call stays low-confidence because the framework itself is a mismatch: CEG benefits from a cyclical demand surge and regulatory wins, not from the adoption curve of a novel innovation platform.
The Forensic SkepticContrarian/Forensic⚫ NeutralLow
Signal: The Calpine acquisition ballooned goodwill from $420M to $11.5B in a single quarter, while TTM free cash flow collapsed to $295M against reported net income of roughly $3.5B, exposing a wide gap between accounting earnings and cash reality. Conviction: Skepticism runs high because 20 of 23 analysts rate it a Buy with an average target of $347, and when consensus is that lopsided on a stock trading at 26x trailing earnings with negligible FCF yield, the margin of safety is gone.
The Moat CompounderValue/Quality/Moat🟢 BullishMed
Signal: The nuclear fleet commands 21% of US capacity with 93%+ utilization rates, and the structural AI-driven electricity demand shift is widening an already narrow but genuine moat built on irreplaceable long-lived assets and high regulatory barriers. Conviction: My conviction is constrained because at 22.5x forward earnings with $24B of net debt and only $295M in TTM free cash flow, this is a fair price for a very good business, not the 20% discount to intrinsic value I prefer before committing capital.
Each view is one investing framework applied to the stock — a perspective, not advice, and identical for every reader. Signals are the panel's own scale, not a recommendation to act.
Where they agree — and where they clash
Common ground
- All five agree AI-driven electricity demand from data centers is a genuine, structural tailwind for CEG's nuclear fleet.
- The Calpine acquisition added heavy leverage ($24B net debt) that every archetype flags as a constraint on the investment case.
- No archetype sees the stock as cheap at $272.88: the bulls see fair value, the neutrals see overvaluation.
- A weekly close above $288 (EMA50) is the shared bullish technical trigger, and a break below $228 is the shared bearish one.
The real debate
- The GARP Operator and The Moat Compounder see a high-quality growth compounder where fair value today is reasonable given the multi-year contracted revenue runway; The Forensic Skeptic sees a leveraged story stock where accounting earnings mask almost no free cash flow.
- The Intrinsic-Value Modeler sees growth largely priced in at 22x forward with narrow upside to his $275 base case; The Moat Compounder would wait for a pullback to $220–230 before deploying serious capital.
- The Disruptive-Innovation Seeker does not even see CEG as fitting the innovation framework: it is a value/growth utility play benefiting from a demand cycle, not a disruptor with compounding platform economics.
The question it comes down to: Can CEG convert its AI-driven contracted revenue pipeline into sufficient free cash flow before the debt taken on in the Calpine acquisition becomes a burden?
The bottom line
- Trigger to confirm the breakout: A weekly close above $288, which coincides with the weekly EMA50 and a high-volume node top, would confirm the correction is over and shift the panel's bias decisively bullish.
- Risk to monitor: A weekly close below $228.63, the established swing low reinforced by the monthly 50% Fibonacci retracement at $232.67, would break structural support and flip the call to SELL.
- Next catalyst: Q3 2026 earnings (expected around October/November) carry a consensus estimate of $3.67 per share; a miss or guidance cut would validate the skeptical case that growth expectations have overshot.
- Further out: Any new major data-center PPA signing or regulatory approval on the Crane Clean Energy Center restart that extends contracted revenue visibility materially beyond five years would lift the Intrinsic-Value Modeler's fair-value range toward $320.
- Balance sheet to watch: Sustained TTM free cash flow above $500M would be the first concrete signal that Calpine integration costs are peaking and the asset is beginning to generate real cash returns, directly addressing The Forensic Skeptic's core objection.
contact@verdixhq.com · Published 2026-08-22 · Prices as of 2026-08-22 · Time horizon: 3–12 months · No direct position held in CEG · CEG verdict history → · Methodology →
Verdix's panel is made up of AI archetypes that apply the well-documented, publicly known investment frameworks of famous investors. They are AI agents — not the investors themselves. Verdix is not affiliated with, endorsed by, or authorized by any real individual, and the archetypes do not represent any real person's actual views, holdings, or statements. Every verdict is AI-generated.
Verdix provides educational equity research and AI-generated multi-perspective analysis. Nothing here constitutes personalized investment advice or a recommendation to buy or sell any security. Verdicts are uniform across all users and do not consider your individual financial situation, risk tolerance, or objectives. Trading and investing involve substantial risk of loss. Past performance does not predict future results. Consult a licensed financial advisor before making investment decisions.
The panel also debated